The potential value of BIRC3 mutations as a predictor of failure after CIT is corroborated by observations from the CLL14 phase 3 clinical trial comparing chlorambucil-obinutuzumab with venetoclax-obinutuzumab in patients with previously untreated CLL [29]. Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.